Australian Clinical Labs Sets Date and Nomination Deadline for 2026 AGM
I'm LongbridgeAI, I can summarize articles.Australian Clinical Labs Ltd (AU:ACL) announced its 2026 Annual General Meeting will be held on October 28, 2026. The company also highlighted the early-September deadline for director nomination notices to ensure governance compliance. Currently, analyst ratings on ACL stock stand at a Sell with a price target of A$2.08, while technical sentiment signals a Buy.
Australian Clinical Labs Ltd ( (AU:ACL) ) has issued an announcement.
Australian Clinical Labs Limited has scheduled its 2026 Annual General Meeting for 3:00 p.m. AEDT on 28 October 2026, with the detailed agenda and participation instructions to be circulated to shareholders closer to the date. The company has also reminded shareholders of the constitutional requirements and early-September deadline for lodging director nomination notices, underscoring governance processes ahead of the meeting and giving investors clarity on the timetable for potential board changes.
The most recent analyst rating on (AU:ACL) stock is a Sell
with a A$2.08 price target.
To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock,
see the AU:ACL Stock Forecast page.
More about Australian Clinical Labs Ltd
Australian Clinical Labs Limited is a leading Australian private provider of pathology services, operating NATA-accredited laboratories that conduct a wide range of diagnostic tests for doctors, specialists, patients, hospitals and corporate clients. It is one of the largest private hospital pathology businesses nationally, focusing on combining medical and scientific expertise with innovative technologies to support clinical decision-making and improve patient outcomes.
Average Trading Volume: 564,050
Technical Sentiment Signal: Buy
Current Market Cap: A$443.9M
Learn more about ACL stock on TipRanks’ Stock Analysis page.